Hemostatic powder TC‐325 treatment of malignancy‐related upper gastrointestinal bleeds: International registry outcomes
| Autor: | Alberto Murino, Edward J. Despott, Paul Bassett, Laurence Lovat, Daniel Mullady, Alvaro de la Serna, Inder Mainie, Michael O'Donnell, Enrique Rodríguez de Santiago, Durayd Alzoubaidi, Johannes W. Rey, Sulleman Moreea, Jason M. Dunn, Bu'Hussain Hayee, Dayna S. Early, Jacobo Ortiz Fernández-Sordo, Phillip Boger, Martin Goetz, Seth A. Gross, Rehan Haidry, John Anderson, Krish Ragunath, Tamas A. Gonda, Tricia Hengehold, David Graham, Emmanuel Coron, Ioannis Varbobitis, Pradeep Bhandari, Ralf Kiesslich, Mohamed Hussein, Melissa Latorre |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Gastrointestinal bleeding medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Malignancy Hemostatics Duodenal Neoplasms Recurrence Stomach Neoplasms Interquartile range Humans Medicine Registries Aged Gastrointestinal Neoplasms Aged 80 and over Minerals Hepatology medicine.diagnostic_test business.industry Hemostasis Endoscopic Gastroenterology Middle Aged medicine.disease Endoscopy Surgery Radiation therapy Treatment Outcome Hemostasis Female Upper gastrointestinal bleeding Powders Gastrointestinal Hemorrhage business Rockall score |
| Zdroj: | Journal of Gastroenterology and Hepatology. 36:3027-3032 |
| ISSN: | 1440-1746 0815-9319 |
| Popis: | Background and Aim: Upper gastrointestinal tumors account for 5% of upper gastrointestinal bleeds. These patients are challenging to treat due to the diffuse nature of the neoplastic bleeding lesions, high rebleeding rates, and significant transfusion requirements. TC-325 (Cook Medical, North Carolina, USA) is a hemostatic powder for gastrointestinal bleeding. The aim of this study was to examine the outcomes of upper gastrointestinal bleeds secondary to tumors treated with Hemospray therapy. Methods: Data were prospectively collected on the use of Hemospray from 17 centers. Hemospray was used during emergency endoscopy for upper gastrointestinal bleeds secondary to tumors at the discretion of the endoscopist as a monotherapy, dual therapy with standard hemostatic techniques, or rescue therapy. Results: One hundred and five patients with upper gastrointestinal bleeds secondary to tumors were recruited. The median Blatchford score at baseline was 10 (interquartile range [IQR], 7–12). The median Rockall score was 8 (IQR, 7–9). Immediate hemostasis was achieved in 102/105 (97%) patients, 15% of patients had a 30-day rebleed, 20% of patients died within 30 days (all-cause mortality). There was a significant improvement in transfusion requirements following treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text